Evaluation of new putative tumor markers for melanoma
- 23 Downloads
Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.
Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.
Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.
Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.
Key WordsMetastatic melanoma Tumor marker Prognosis
Unable to display preview. Download preview PDF.
- 1.Schutter EMJ, Visser JJ, van Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy: a review of the literature.Tumor Biol 1992;13:121–32.Google Scholar
- 8.Springall DR, Gu J, Cocchia D, et al. The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas: a comparative study using S-100 and neuron-specific enolase antibodies.Virchows Arch Pathol Anat 1983;400:331–43.Google Scholar
- 11.Kaplan FL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;52:457–81.Google Scholar
- 13.Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized trials requiring prolonged observation of each patient II. analysis and examples.Br J Cancer 1997;35:1–39.Google Scholar
- 14.Cox DR. Regression models life tables.J R Stat Soc 1972;34:187–220.Google Scholar
- 15.Bartolucci AA, Fraser MD. Comparative step-upward composite tests for selecting prognostic indicators associated with survival.Biomet J 1977:19;437–48.Google Scholar
- 21.Clark HB, Santa Cruz D, Hartman BK, Moore BW. S-100 protein, an immunohistochemical marker for malignant melanoma and other melanocytic lesions [Abstract].Lab Invest 1982;46:13A.Google Scholar
- 26.Kirkwood JM. Present and future applications of the interferons in melanoma [Abstract]. 38th Annual Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. M.D. Anderson Cancer Center, Houston, February 1995.Google Scholar
- 27.Cascinelli N. Evaluation of efficacy of adjuvant rIFN-α 2A in melanoma patients with regional node metastases [Abstract 1296].Proc Am Soc Clin Oncol 1995;14:410.Google Scholar